达丁类药物的使用与痛风患者关节骨折风险降低有关
Chun-Ming Chen1, Wan-Ting Huang2, Sheng-Feng Sung3,4
1Division of Allergy, Immunology, and Rheumatology, Department of Internal Medicine, Ditmanson Medical Foundation Chia-Yi Christian Hospital, Chiayi 60002, Taiwan.
Bone reports
|September 10, 2024
概括
在50-64岁的痛风患者中,使用他类药物显著降低了关节骨折的风险,特别是在女性中,她们也显示了脊椎骨折风险的降低. 老年痛风患者没有体验到这些好处.
科学领域:
- 类风湿病学 类风湿病学
- 老年学是一门学科.
- 药理学 药理学是指药理学的学科.
背景情况:
- 已知他类药物可降低骨折风险并改善骨矿物质密度.
- 对于痛风患者的骨折风险,他类药物的使用的影响仍未得到研究.
研究的目的:
- 研究使用他类药物的临床有效性,以减少痛风患者中骨折风险.
主要方法:
- 使用台湾国家健康保险研究数据库进行的回顾性队列研究.
- 包括使用他类药物的3443名痛风患者和6886名匹配的非他类药物使用者 (50岁以上).
- 考克斯比例危险回归分析用于评估骨折风险.
主要成果:
- 在痛风患者中,使用静止剂与关节骨折风险降低有关 (aHR=0.78,95% CI=0.64-0.94).
- 这种保护作用在50-64岁的男性和女性 (aHR≈0.35) 中显著,但在老年人中没有显著.
- 使用他类药物的50-64岁妇女的脊椎骨折风险较低 (aHR=0.70,95% CI=0.50-0.99).
结论:
- 静止剂的使用可能会降低年轻的痛风患者 (50-64岁) 的骨折风险.
- 需要进一步的研究来证实这些发现,并探索机制.
- 这些好处似乎是针对年轻年龄组和某些骨折类型的.
更多相关视频
相关概念视频
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
588
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
588
Dipeptidyl Peptidase 4 Inhibitors
178
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
178
Peptic Ulcer Disease IV: Management
75
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
75
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
499
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
499
Drugs that Stabilize Microtubules
2.0K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.0K
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
167
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
167


